Published in Mol Cell on October 12, 2007
In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab (2013) 1.93
pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J (2008) 1.72
The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ (2008) 1.61
NF-κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res (2010) 1.58
Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol (2008) 1.54
New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.31
The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene (2011) 1.30
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res (2009) 1.18
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell (2013) 1.15
Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med (2011) 1.13
Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PLoS One (2010) 1.12
Regulation of NF-κB by the CARD proteins. Immunol Rev (2012) 1.12
Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem (2013) 1.12
Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Rep (2014) 1.04
Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization. PLoS One (2010) 1.04
Systemic VHL gene functions and the VHL disease. FEBS Lett (2012) 0.94
The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR. PLoS One (2011) 0.93
The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des (2009) 0.93
Identification of a novel transport-independent function of PiT1/SLC20A1 in the regulation of TNF-induced apoptosis. J Biol Chem (2010) 0.93
Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms. Oncogene (2011) 0.92
Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. EMBO Mol Med (2010) 0.90
Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective. J Interferon Cytokine Res (2013) 0.89
The role of hypoxia in inflammatory disease (review). Int J Mol Med (2015) 0.89
Renal cancer: oxygen meets metabolism. Exp Cell Res (2012) 0.88
The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL). Oncogene (2009) 0.88
Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. Cancer Discov (2013) 0.87
The interaction of the von Hippel-Lindau tumor suppressor and heterochromatin protein 1. Arch Biochem Biophys (2012) 0.86
Implications of protein post-translational modifications in IBD. Inflamm Bowel Dis (2012) 0.86
Early cellular signaling responses to axonal injury. Cell Commun Signal (2009) 0.86
The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet (2015) 0.85
Inadequate activation of the GTPase RhoA contributes to the lack of fibronectin matrix assembly in von Hippel-Lindau protein-defective renal cancer cells. J Biol Chem (2008) 0.85
The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer. Front Oncol (2012) 0.84
Meta-analysis identifies NF-κB as a therapeutic target in renal cancer. PLoS One (2013) 0.83
The structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions. Cell Div (2016) 0.82
Drosophila VHL tumor-suppressor gene regulates epithelial morphogenesis by promoting microtubule and aPKC stability. Development (2010) 0.82
Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma. Cancer Res (2013) 0.82
NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma. Mol Cancer Ther (2013) 0.82
Drosophila von Hippel-Lindau tumor suppressor gene function in epithelial tubule morphogenesis. Mol Cell Biol (2010) 0.82
Kidney cancer pathology in the new context of targeted therapy. Pathobiology (2011) 0.81
The von Hippel-Lindau protein pVHL inhibits ribosome biogenesis and protein synthesis. J Biol Chem (2013) 0.81
ZBRK1, a novel tumor suppressor, activates VHL gene transcription through formation of a complex with VHL and p300 in renal cancer. Oncotarget (2015) 0.81
pVHL mediates K63-linked ubiquitination of nCLU. PLoS One (2012) 0.78
The expression level of the transcription factor Aryl hydrocarbon receptor nuclear translocator (ARNT) determines cellular survival after radiation treatment. Radiat Oncol (2015) 0.77
Structural insights into the folding defects of oncogenic pVHL lead to correction of its function in vitro. PLoS One (2013) 0.76
USP9X destabilizes pVHL and promotes cell proliferation. Oncotarget (2016) 0.75
A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization. Oncogene (2015) 0.75
Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces "angiogenic switch off" in a hepatoma mouse model. Mol Ther Oncolytics (2015) 0.75
Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget (2016) 0.75
[Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer]. Pathologe (2008) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (1996) 13.87
Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science (1996) 12.23
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (1996) 11.29
Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol (2004) 9.05
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature (2003) 6.53
Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol (2005) 6.44
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 6.32
Cloning of a factor required for activity of the Ah (dioxin) receptor. Science (1991) 5.84
Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer (2002) 5.63
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature (2006) 5.34
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 5.14
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science (1995) 4.93
Tumour suppression by the human von Hippel-Lindau gene product. Nat Med (1995) 4.71
Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A (2001) 4.60
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 4.13
Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science (2002) 3.86
Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature (2002) 3.78
Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer (2005) 3.72
A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. EMBO Rep (2001) 3.67
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell (2005) 3.51
A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A (2006) 2.90
von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet (2001) 2.79
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Von Hippel-Lindau disease. Annu Rev Pathol (2007) 2.61
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet (2001) 2.56
Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J (2006) 2.41
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res (2004) 2.27
Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene (2003) 1.93
CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B. J Biol Chem (2000) 1.89
Recombination signal sequence binding protein Jkappa is constitutively bound to the NF-kappaB site of the interleukin-6 promoter and acts as a negative regulatory factor. Mol Cell Biol (1997) 1.87
Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans. PLoS Biol (2004) 1.72
Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis (2003) 1.37
The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. Cancer Res (2003) 1.30
Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene (2001) 1.30
Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol (2005) 1.22
von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res (2006) 1.14
von Hippel-Lindau tumor suppressor: not only HIF's executioner. Trends Mol Med (2004) 1.12
All roads lead to CARD9. Nat Immunol (2007) 1.10
VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. Oncogene (2005) 1.05
Polycythemia: mechanisms and management. Ann Intern Med (1981) 0.97
Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain. J Biol Chem (2005) 0.95
PromoterExplorer: an effective promoter identification method based on the AdaBoost algorithm. Bioinformatics (2006) 0.94
Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol (2000) 0.93
Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFalpha cytotoxicity. Oncogene (2002) 0.90
Analysis of von Hippel-Lindau hereditary cancer syndrome: implications of oxygen sensing. Methods Enzymol (2004) 0.87
Interferon-alpha suppresses the antiapoptotic effect of NF-kB and sensitizes renal cell carcinoma cells in vitro to chemotherapeutic drugs. Eur Urol (2001) 0.85
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell (2012) 7.09
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell (2011) 7.03
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 6.32
Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12
Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol (2006) 5.92
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature (2010) 5.43
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol (2003) 5.14
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74
A robust DNA mechanical device controlled by hybridization topology. Nature (2002) 4.45
Ribosomopathies: human disorders of ribosome dysfunction. Blood (2010) 4.43
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature (2012) 4.37
Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell (2012) 4.29
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell (2003) 4.13
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A (2002) 4.03
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
mirWIP: microRNA target prediction based on microRNA-containing ribonucleoprotein-enriched transcripts. Nat Methods (2008) 3.88
Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science (2002) 3.86
MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell (2008) 3.84
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature (2004) 3.63
Chemosensitivity linked to p73 function. Cancer Cell (2003) 3.63
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell (2005) 3.51
Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell (2009) 3.50
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell (2005) 3.47
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell (2010) 3.46
Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov (2011) 3.45
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet (2009) 3.10
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol (2008) 2.93
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Genetic evidence supports demic diffusion of Han culture. Nature (2004) 2.92
Transcriptome profiling, molecular biological, and physiological studies reveal a major role for ethylene in cotton fiber cell elongation. Plant Cell (2006) 2.87
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood (2010) 2.84
Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res (2008) 2.75
Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol (2011) 2.69
Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am J Hum Genet (2008) 2.65
Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proc Natl Acad Sci U S A (2007) 2.60
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol (2006) 2.60
Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A (2005) 2.54
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood (2007) 2.51
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med (2010) 2.50
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A (2014) 2.46
Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis (2005) 2.44
Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J (2006) 2.41
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell (2012) 2.39
Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science (2011) 2.36
Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell (2005) 2.35
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev (2013) 2.31
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A (2008) 2.27
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol (2012) 2.25
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A (2004) 2.25
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood (2011) 2.23
Microarray-based gene expression profiles in multiple tissues of the domesticated silkworm, Bombyx mori. Genome Biol (2007) 2.21
Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging (2003) 2.17
Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet (2012) 2.17
Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell (2009) 2.15
Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol Cell (2008) 2.15
VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol (2006) 2.03
Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells. Cancer Res (2003) 2.00
Regulation of endocytosis via the oxygen-sensing pathway. Nat Med (2009) 2.00
HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest (2003) 1.99
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell (2004) 1.98
Q&A: Cancer: clues from cell metabolism. Nature (2010) 1.98
Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest (2011) 1.96
Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell (2010) 1.95
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol (2007) 1.92
Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther (2010) 1.90